06 February 2025
In one of the biggest deals worldwide for a biosimilar brand, Ahmedabad-based Intas agreed to buy Udenyca-the brand name for medication pegfilgrastim-cbqv-from US-based Coherus BioSciences. Udenyca will be sold in the US by Accord BioPharma, the specialty division of Intas Pharma.
Intas Pharmaceuticals' acquisition of Udenyca for up to $558.4 million (about Rs 4,784 crore) will pit it against other leading biosimilar makers like Biocon, Amgen, Pfizer, Fresenius Kabi and Sandoz in the fast-growing global market for oncology treatment.
In one of the biggest deals worldwide for a biosimilar brand, Ahmedabad-based Intas agreed to buy Udenyca-the brand name for medication pegfilgrastim-cbqv-from US-based Coherus BioSciences. Udenyca will be sold in the US by Accord BioPharma, the specialty division of Intas Pharma.
Intas Pharmaceuticals' acquisition of Udenyca for up to $558.4 million (about Rs 4,784 crore) will pit it against other leading biosimilar makers like Biocon, Amgen, Pfizer, Fresenius Kabi and Sandoz in the fast-growing global market for oncology treatment.
Stay Connected, Stay Informed –
Don’t miss out on exclusive updates, market trends, and real-time investment opportunities. Be the first to know about the latest unlisted stocks, IPO announcements, and curated Fact Sheets, delivered straight to your WhatsApp.